Abstract
PURPOSE
This study was conducted to evaluate the clinical efficacy and safety of computed
tomography (CT)-guided 125I implantation in the treatment of recurrent or metastatic pelvic malignant tumor.
METHODS AND MATERIALS
This retrospective study analyzed the data of 30 patients with recurrent and metastatic
pelvic malignant tumor who were treated with CT-guided 125I implantation between January 2016 and December 2020. Disease control rate, objective
remission rate, overall survival (OS), pain relief rate, quality of life score, and
complications were evaluated after the followup.
RESULTS
Median followup was 20.1 (7–30) months. Disease control rate was 86.67% at 6 months.
Objective response rates at 1, 3, and 6 months were 36.67%, 60%, and 56.67%, respectively.
OS rates at 12 and 24 months were 76.67% (23/30) and 33.33% (10/30), respectively.
Progression-free survival rates at 12 and 24 months were 63.33% (19/30) and 33.33%
(10/30), respectively. Postoperative pain relief rate was 86.67% (26/30). There were
no major bleeding, pelvic abscess, intestinal fistula, intestinal perforation, and
other serious complications.
CONCLUSIONS
CT-guided 125I seed implantation in the treatment of patients with pelvic malignant tumor is a
simple operation and less traumatic and can improve patients’ quality of life and
reduce tumor load.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to BrachytherapyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Novel therapeutics for recurrent cervical cancer: moving towards personalized therapy.Drugs. 2020; 80: 217-227
- Pharmacological treatment of patients with metastatic, recurrent or persistent cervical cancer not amenable by surgery or radiotherapy: state of art and perspectives of clinical research.Cancers. 2020; 12: 2678
- Does pelvic radiation increase rectal cancer incidence? - A systematic review and meta-analysis.Cancer Treatment Rev. 2018; 68: 136-144
- Long-term outcomes and prognostic analysis of computed tomography-guided radioactive (125)I seed implantation for locally recurrent rectal cancer after external beam radiotherapy or surgery.Front Oncol. 2020; 10540096
- Advances in brachytherapy for recurrent cervical cancer.Chin. J. Radiat. Oncol. 2021; 30: 297-300
- Expert consensus workshop report: guideline for three-dimensional printing template-assisted computed tomography-guided (125)I seeds interstitial implantation brachytherapy.J Cancer Res Ther. 2017; 13: 607-612
- New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).Eur J Cancer (Oxford, England: 1990). 2009; 45: 228-247
- Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC).Int J Radiat Oncol Biol Phys. 1995; 31: 1341-1346
- A systematic review of the pain scales in adults: which to use?.Am J Emerg Med. 2018; 36: 707-714
- Diagnostic strategies for recurrent cervical cancer: a cohort study.Front Oncol. 2020; 10591253
- NCCN guidelines insights: rectal cancer, Version 6.2020.J Natl Comprehens Cancer Netw: JNCCN. 2020; 18: 806-815
- Colon cancer, version 2.2021, NCCN clinical practice guidelines in oncology.J Natl Comprehens Cancer Netw: JNCCN. 2021; 19: 329-359
- Complications and 5-year survival after radical resections which include urological organs for locally advanced and recurrent pelvic malignancies: analysis of 646 consecutive cases.Tech Coloproctol. 2020; 24: 181-190
- Adjuvant chemotherapy does not improve recurrence-free survival in patients with stage 2 or stage 3 rectal cancer after neoadjuvant chemoradiotherapy and total mesorectal excision.Dis Colon Rectum. 2020; 63: 427-440
- Extended-field radiotherapy for locally advanced cervical cancer.Cochrane Database Syst Rev. 2018; 10CD012301
- Expert consensus statement on computed tomography-guided (125)I radioactive seeds permanent interstitial brachytherapy.J Cancer Res Ther. 2018; 14: 12-17
- Efficacy and safety of CT-guided (125)I seed implantation as a salvage treatment for locally recurrent head and neck soft tissue sarcoma after surgery and external beam radiotherapy: a 12-year study at a single institution.Brachytherapy. 2020; 19: 81-89
- Radioactive (125)I seed implantation for locally advanced pancreatic cancer: a retrospective analysis of 50 cases.World J Clin Cases. 2020; 8: 3743-3750
- Oligorecurrence non-small cell lung cancer after failure of first-line chemotherapy: computed tomography-guided I seed implantation vs. Second-Line Chemotherapy.Front. Oncol. 2020; 10: 470
- Therapeutic effects and prognostic factors of I brachytherapy for pelvic recurrence after early cervical cancer surgery.Sci. Rep. 2021; 11: 11356
- Efficacy and dosimetry analysis of image-guided radioactive 125I seed implantation as salvage treatment for pelvic recurrent cervical cancer after external beam radiotherapy.J Gynecol Oncol. 2019; 30: e9
- (125)I implantation under computed tomography guidance to treat patients with recurrent pelvic tumors: retrospective analysis of clinical results.J Cancer Res Ther. 2019; 15: 1496-1500
Article info
Publication history
Published online: December 29, 2022
Accepted:
October 21,
2022
Received in revised form:
October 7,
2022
Received:
April 22,
2022
Publication stage
In Press Corrected ProofFootnotes
Disclosures: This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. The authors report no proprietary or commercial interest in any product mentioned or concept discussed in this article.
Identification
Copyright
© 2022 American Brachytherapy Society. Published by Elsevier Inc. All rights reserved.
